
Capricor Therapeutics Investors Face September Deadline in Fraud Suit
Investors who incurred financial losses holding Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, have until September 28 to seek lead plaintiff status. The Law Offices of Frank R. Cruz is spearheading the class action litigation, targeting alleged misrepresentations surrounding the company’s clinical trial data.
























